Mesenchymal Stem Cell Therapies in the Treatment of Musculoskeletal Diseases

PM and R

Volumn 6, Issue 1, 2014, Pages 61-69

  Bashir, Jamil ^a   Sherman, Andrew ^a   Lee, Henry ^a   Kaplan, Lee ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; TISSUE SCAFFOLD;

ADIPOSE TISSUE; BONE MARROW; CARTILAGE INJURY; CELL DIFFERENTIATION; CELL PROLIFERATION; ENGRAFTMENT; EX VIVO STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; LIGAMENT INJURY; MESENCHYMAL STEM CELL TRANSPLANTATION; MUSCULOSKELETAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYSTEMATIC REVIEW; TENDON INJURY; TENDON RECONSTRUCTION; THROMBOCYTE RICH PLASMA; UPREGULATION; VISUAL ANALOG SCALE;

ANIMALS; CARTILAGE DISEASES; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; GUIDELINES AS TOPIC; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOARTHRITIS; PLATELET-RICH PLASMA; REGENERATION; T-LYMPHOCYTES; TENDON INJURIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE SCAFFOLDS;

EID: 84892462463     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2013.05.007     Document Type: Review

References (66)

1. Couppe C., Hansen P., Kongsgaard M., et al. Mechanical properties and collagen cross-linking of the patellar tendon in old and young men. J Appl Physiol 2009, 107(3):880-886.
2. Buckwalter J.A. Maintaining and restoring mobility in middle and old age: The importance of the soft tissues. Instr Course Lect 1997, 46:459-469.
3. U.S. Bone & Joint Decade. The Burden of Musculoskeletal Diseases in the United States. 2008. Available at Accessed May 29, 2013. http://www.boneandjointburden.org/.
4. Williams A.R., Hare J.M. Mesenchymal stem cells: Biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011, 109(8):923-940.
5. da Silva M.L., Caplan A.I., Nardi N.B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26(9):2287-2299.
6. Pittenger M.F. Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 2008, 449:27-44.
7. Centeno C.J., Busse D., Kisiday J., Keohan C., Freeman M., Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician 2008, 11(3):343-353.
8. Centeno C.J., Busse D., Kisiday J., Keohan C., Freeman M., Karli D. Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells. Med Hypotheses 2008, 71(6):900-908.
9. Lysaght T., Campbell A.V. Regulating autologous adult stem cells: The FDA steps up. Cell Stem Cell 2011, 9(5):393-396.
10. Meirelles L.S., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20(5-6):419-427.
11. Caplan A.I., Correa D. The MSC: An injury drugstore. Cell Stem Cell 2011, 9(1):11-15.
12. Takashima Y., Era T., Nakao K., et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 2007, 129(7):1377-1388.
13. Ma T. Mesenchymal stem cells: From bench to bedside. World J Stem Cells 2010, 2(2):13-17.
14. Chamberlain G., Fox J., Ashton B., Middleton J. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007, 25(11):2739-2749.
15. Stolzing A., Jones E., McGonagle D., Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies. Mech Ageing Dev 2008, 129(3):163-173.
16. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98(5):1076-1084.
17. Lindner U., Kramer J., Rohwedel J., Schlenke P. Mesenchymal stem or stromal cells: Toward a better understanding of their biologyα. Transfus Med Hemother 2010, 37(2):75-83.
18. Majd H., Quinn T.M., Wipff P.J., Hinz B. Dynamic expansion culture for mesenchymal stem cells. Methods Mol Biol 2011, 698:175-188.
19. Giordano A., Galderisi U., Marino I.R. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007, 211(1):27-35.
20. Halleux C., Sottile V., Gasser J.A., Seuwen K. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskelet Neuronal Interact 2001, 2(1):71-76.
21. Schmitt A., van G.M., Imhoff A.B., Buchmann S. Application of stem cells in orthopedics. Stem Cells Int 2012, 2012:394962.
22. Fong E.L., Chan C.K., Goodman S.B. Stem cell homing in musculoskeletal injury. Biomaterials 2011, 32(2):395-409.
23. Nguyen R.T., Borg-Stein J., McInnis K. Applications of platelet-rich plasma in musculoskeletal and sports medicine: An evidence-based approach. PM R 2011, 3(3):226-250.
24. Kajikawa Y., Morihara T., Sakamoto H., et al. Platelet-rich plasma enhances the initial mobilization of circulation-derived cells for tendon healing. J Cell Physiol 2008, 215(3):837-845.
25. Kumar S., Ponnazhagan S. Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect. Bone 2012, 50(4):1012-1018.
26. Shabbir A., Zisa D., Suzuki G., Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: A noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 2009, 296(6):H1888-H1897.
27. Nixon A.J., Watts A.E., Schnabel L.V. Cell- and gene-based approaches to tendon regeneration. J Shoulder Elbow Surg 2012, 21(2):278-294.
28. Doorn J., Moll G., Le B.K., van B.C., de B.J. Therapeutic applications of mesenchymal stromal cells: Paracrine effects and potential improvements. Tissue Eng Part B Rev 2012, 18(2):101-115.
29. Jiang X.X., Zhang Y., Liu B., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105(10):4120-4126.
30. Uccelli A., Moretta L., Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006, 36(10):2566-2573.
31. Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23(5):471-478.
32. Lozito T.P., Tuan R.S. Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs. J Cell Physiol 2011, 226(2):385-396.
33. Caplan A.I. All MSCs are pericytesα. Cell Stem Cell 2008, 3(3):229-230.
34. U.S. Food and Drug Administration. CFR-Code of Federal Regulations, Title 21. Available at Accessed May 29, 2012. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cf?CFRPart=1271.
35. Halme D.G., Kessler D.A. FDA regulation of stem-cell-based therapies. N Engl J Med 2006, 355(16):1730-1735.
36. Sipp D., Turner L. U.S.regulation of stem cells as medical products. Science 2012, 338:1296-1297.
37. Cyranoski D. FDA's claims over stem cells upheld: Drug watchdog wins right to regulate controversial therapies. Nature 2012, 488:14.
38. Ahmad Z., Wardale J., Brooks R., Henson F., Noorani A., Rushton N. Exploring the application of stem cells in tendon repair and regeneration. Arthroscopy 2012, 28(7):1018-1029.
39. Lu C.H., Chang Y.H., Lin S.Y., Li K.C., Hu Y.C. Recent progresses in gene delivery-based bone tissue engineering. Biotechnol Adv 2013, 31:1695-1706.
40. Gulotta L.V., Kovacevic D., Packer J.D., Deng X.H., Rodeo S.A. Bone marrow-derived mesenchymal stem cells transduced with scleraxis improve rotator cuff healing in a rat model. Am J Sports Med 2011, 39(6):1282-1289.
41. Sato M., Uchida K., Nakajima H., et al. Direct transplantation of mesenchymal stem cells into the knee joints of Hartley strain guinea pigs with spontaneous osteoarthritis. Arthritis Res Ther 2012, 14(1):R31.
42. Somers P., Cornelissen R., Thierens H., Van N.G. An optimized growth factor cocktail for ovine mesenchymal stem cells. Growth Factors 2012, 30(1):37-48.
43. Chen C.C., Liao C.H., Wang Y.H., et al. Cartilage fragments from osteoarthritic knee promote chondrogenesis of mesenchymal stem cells without exogenous growth factor induction. J Orthop Res 2012, 30(3):393-400.
44. Bedi A., Maak T., Walsh C., et al. Cytokines in rotator cuff degeneration and repair. J Shoulder Elbow Surg 2012, 21(2):218-227.
45. Lyras D.N., Kazakos K., Verettas D., et al. The influence of platelet-rich plasma on angiogenesis during the early phase of tendon healing. Foot Ankle Int 2009, 30(11):1101-1106.
46. Rodkey W.G., DeHaven K.E., Montgomery W.H., et al. Comparison of the collagen meniscus implant with partial meniscectomy. A prospective randomized trial. J Bone Joint Surg Am 2008, 90(7):1413-1426.
47. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: A case series. J Med Case Rep 2011, 5:296.
48. Davatchi F., Abdollahi B.S., Mohyeddin M., Shahram F., Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011, 14(2):211-215.
49. Centeno C.J., Schultz J.R., Cheever M., Robinson B., Freeman M., Marasco W. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther 2010, 5(1):81-93.
50. Centeno C.J., Schultz J.R., Cheever M., et al. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther 2011, 6(4):368-378.
51. Connell D., Datir A., Alyas F., Curtis M. Treatment of lateral epicondylitis using skin-derived tenocyte-like cells. Br J Sports Med 2009, 43(4):293-298.
52. Clarke A.W., Alyas F., Morris T., Robertson C.J., Bell J., Connell D.A. Skin-derived tenocyte-like cells for the treatment of patellar tendinopathy. Am J Sports Med 2011, 39(3):614-623.
53. Mafi R., Hindocha S., Mafi P., Griffin M., Khan W.S. Sources of adult mesenchymal stem cells applicable for musculoskeletal applications-a systematic review of the literature. Open Orthop J 2011, 5(suppl 2):242-248.
54. Bi Y., Ehirchiou D., Kilts T.M., et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007, 13(10):1219-1227.
55. Lui P.P., Chan K.M. Tendon-derived stem cells (TDSCs): From basic science to potential roles in tendon pathology and tissue engineering applications. Stem Cell Rev 2011, 7(4):883-897.
56. Tan Q., Lui P.P., Rui Y.F., Wong Y.M. Comparison of potentials of stem cells isolated from tendon and bone marrow for musculoskeletal tissue engineering. Tissue Eng Part A 2012, 18(7-8):840-851.
57. Nagata M.J., Messora M.R., Furlaneto F.A., et al. Effectiveness of two methods for preparation of autologous platelet-rich plasma: An experimental study in rabbits. Eur J Dent 2010, 4(4):395-402.
58. Araki J., Jona M., Eto H., et al. Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: Maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods 2012, 18(3):176-185.
59. Sadoghi P., Lohberger B., Aigner B., et al. Effect of platelet-rich plasma on the biologic activity of the human rotator-cuff fibroblasts: A controlled in vitro study. J Orthop Res 2013 Apr 8, [E-pub ahead of print].
60. Molloy T., Wang Y., Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med 2003, 33(5):381-394.
61. Zarembinski T.I., Tew W.P., Atzet S.K. The use of a hydrogel matrix as a cellular delivery vehicle in future cell-based therapies: Biological and non-biological considerations. Regenerative Medicine and Tissue Engineering-Cells and Biomaterials 2011, InTech, Available at, Accessed May 29, 2013. http://www.intechopen.com/books/regenerative-medicine-and-tissue-engineering-cells-and-biomaterials/the-use-of-a-hydrogel-matrix-as-a-cellular-delivery-vehicle-in-future-cell-based-therapies-biologica, D. Eberli (Ed.).
62. Wu X., Ren J., Li J. Fibrin glue as the cell-delivery vehicle for mesenchymal stromal cells in regenerative medicine. Cytotherapy 2012, 14(5):555-562.
63. Hatzistergos K.E., Blum A., Ince T.A., Grichnik J.M., Hare J.M. What is the oncologic risk of stem cell treatment for heart diseaseα. Circ Res 2011, 108:1300-1303.
64. Wang Y., Han Z.B., Song Y.P., Han Z.C. Safety of mesenchymal stem cells for clinical application. Stem Cells Int 2012, 2012:652034.
65. Rangarajan A., Hong S.J., Gifford A., Weinberg R.A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6(2):171-183.
66. Heldman A.W., Difede D.L., Fishman J.E., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014, 311:62-73.